PlasmaGen raises ₹150 crore, valuation crosses ₹1,500 crore
In a significant development in the Indian healthcare sector, Bengaluru-based PlasmaGen Biosciences has raised ₹150 crore in a funding round led by ViNS Bioproducts. This investment has propelled the company’s valuation to over ₹1,500 crore, cementing its position as a leading player in the plasma fractionation industry. With this funding, PlasmaGen has now raised over ₹600 crore to date, demonstrating the confidence of investors in its vision and capabilities.
PlasmaGen Biosciences is a pioneering company in the field of plasma fractionation, which involves the process of extracting life-saving therapies from human plasma. The company operates one of India’s five plasma fractionation facilities near Bengaluru, which is equipped with state-of-the-art technology to produce high-quality plasma-derived products. These products are used to treat a range of serious diseases, including hemophilia, immunodeficiency disorders, and critical care conditions.
The funding round was led by ViNS Bioproducts, a leading biotechnology company with a strong track record of investing in innovative healthcare ventures. PlasmaGen is also backed by prominent investors such as Eight Roads, FIL Capital, and F-Prime, which have supported the company’s growth and expansion plans. The participation of these esteemed investors is a testament to PlasmaGen’s commitment to delivering high-quality products and its potential to make a significant impact in the global healthcare market.
The plasma fractionation industry is a highly specialized and complex field, requiring significant investment in infrastructure, technology, and talent. PlasmaGen’s ability to attract top-tier investors and raise substantial funding is a reflection of its expertise and capabilities in this domain. The company’s facility near Bengaluru is designed to meet international standards, with a focus on quality, safety, and regulatory compliance.
The demand for plasma-derived products is increasing globally, driven by the growing prevalence of diseases such as hemophilia and immunodeficiency disorders. India, with its large population and increasing healthcare needs, is an important market for these products. PlasmaGen is well-positioned to capitalize on this trend, with its advanced manufacturing facility and strong distribution network.
The company’s products are used to treat a range of serious diseases, including:
- Hemophilia: a genetic disorder that affects the blood’s ability to clot, requiring regular infusions of clotting factor concentrates.
- Immunodeficiency disorders: conditions such as primary immunodeficiency diseases, which require immunoglobulin replacement therapy to prevent infections.
- Critical care conditions: such as sepsis, trauma, and burns, which require plasma-derived products to support patient recovery.
PlasmaGen’s commitment to quality and safety is evident in its rigorous testing and quality control processes, which ensure that its products meet the highest standards of purity and potency. The company’s products are also subject to strict regulatory oversight, with compliance with international standards such as those set by the US FDA and the European Medicines Agency.
The funding raised by PlasmaGen will be used to further expand its manufacturing capacity, invest in research and development, and enhance its distribution network. The company plans to increase its production of plasma-derived products, which will enable it to meet the growing demand for these life-saving therapies in India and globally.
In conclusion, PlasmaGen Biosciences’ ₹150 crore funding round is a significant milestone for the company, valuing it at over ₹1,500 crore. With the support of prominent investors such as ViNS Bioproducts, Eight Roads, FIL Capital, and F-Prime, PlasmaGen is well-positioned to continue its growth trajectory and make a meaningful impact in the global healthcare market. As the company expands its operations and increases its production of plasma-derived products, it will play an increasingly important role in saving lives and improving healthcare outcomes in India and beyond.
News Source: https://ascendants.in/funding-feed/plasmagen-biosciences-raises-rs-150-cr/
About the Author
